These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 1903843)

  • 21. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
    Antonela Antoniu S
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
    Westerman EM; Heijerman HG; Frijlink HW
    Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
    Zabner R; Quinn JP
    Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
    J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eradication therapy for early Pseudomonas aeruginosa infection in CF: many questions still unanswered.
    Jones AM
    Eur Respir J; 2005 Sep; 26(3):373-5. PubMed ID: 16135714
    [No Abstract]   [Full Text] [Related]  

  • 26. Eradication of Pseudomonas aeruginosa in cystic fibrosis.
    Eber E; Thalhammer GH; Zach MS
    Eur Respir J; 2006 Feb; 27(2):438-9. PubMed ID: 16452606
    [No Abstract]   [Full Text] [Related]  

  • 27. MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.
    Azoicai D; Antoniu SA
    Expert Opin Investig Drugs; 2013 Feb; 22(2):267-76. PubMed ID: 23176385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
    Langan KM; Kotsimbos T; Peleg AY
    Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis.
    VanDevanter DR; Ballmann M; Flume PA
    Respir Med; 2011 Dec; 105 Suppl 2():S18-23. PubMed ID: 22208544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Strategy of antibiotic therapy in the course of chronic Pseudomonas aeruginosa infection].
    Bassinet L
    Rev Mal Respir; 2003 Apr; 20(2 Pt 2):S118-28. PubMed ID: 12910144
    [No Abstract]   [Full Text] [Related]  

  • 37. [Cystic fibrosis: current therapy. Antibiotics].
    Tamm M; Héritier F; Rappaz I; Schaad UB
    Schweiz Med Wochenschr Suppl; 2000; 122():33S-37S. PubMed ID: 12536469
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation.
    Prescrire Int; 2002 Dec; 11(62):177-8. PubMed ID: 12469696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Ratjen F
    Curr Opin Pulm Med; 2006 Nov; 12(6):428-32. PubMed ID: 17053493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.